Kalkine has a fully transformed New Avatar.

small-cap

An Update on One NASDAQ- Listed Biopharmaceuticals Stock– G1 Therapeutics Inc

Aug 07, 2024 | Team Kalkine
An Update on One NASDAQ- Listed Biopharmaceuticals Stock– G1 Therapeutics Inc

G1 Therapeutics Inc

G1 Therapeutics, Inc. (NASDAQ: GTHX) is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy.

Recent Business and Financial Updates

  • Pharmacosmos Group to Acquire G1 Therapeutics
    • Enhanced Patient Access: The acquisition aims to provide patients with extensive-stage small cell lung cancer (ES-SCLC) optimal access to G1’s COSELA® (trilaciclib), a proactive multilineage myeloprotection agent.
    • Maximized Availability: Pharmacosmos’ resources and expertise in hematology and supportive care will maximize COSELA's availability for ES-SCLC patients.
    • Expanded Global Portfolio: The transaction will expand and strengthen Pharmacosmos’ global commercial portfolio.
    • Shareholder Value: G1’s shareholders will receive USD 7.15 per share in cash, totaling approximately USD 405 million in equity value.
    • Details:
      • Agreement: Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire all outstanding shares of G1 Therapeutics common stock for USD 7.15 per share.
      • Premium: This represents a 68% premium to G1’s closing share price on August 6, 2024, and a 133% premium to G1’s prior 30-day volume-weighted average price.
      • Approval: The Boards of Directors of both companies have unanimously approved the transaction, expected to close late in the third quarter of 2024.
    • Strategic Fit:
      • COSELA: G1’s COSELA is the first FDA-approved product to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with ES-SCLC.
      • Collaboration: The combined company will leverage Pharmacosmos’ global commercial presence and significant resources to enhance COSELA’s availability and optimize its commercial reach to oncologists.
    • G1 Therapeutics to Release Q2 2024 Financial Results and Business Update: G1 Therapeutics, Inc. (Nasdaq: GTHX) will host a webcast and conference call on August 8, 2024, at 8:30 a.m. ET to provide a financial and corporate update for the second quarter of 2024.
    • G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): G1 Therapeutics, Inc. (Nasdaq: GTHX) announced the grant of inducement stock options for 12,300 shares and 6,150 restricted stock units (RSUs) to five new employees under its Amended and Restated 2021 Inducement Equity Incentive Plan. These awards, granted as a material inducement to employment, are in accordance with Nasdaq Listing Rule 5635(c)(4).
    • G1 Therapeutics Added to the Russell 2000® and 3000® Indexes: G1 Therapeutics, Inc. (Nasdaq: GTHX) announced its inclusion in the Russell 2000® and Russell 3000® Indexes following the 2024 Russell US Indexes annual reconstitution, effective July 1, 2024. This inclusion reflects the company's ranking among the 4,000 largest U.S. stocks by market capitalization and underscores its growing prominence in the market.
    • G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (mTNBC): G1 Therapeutics announced that the Phase 3 PRESERVE 2 trial did not achieve statistical significance in the primary endpoint of overall survival (OS) for patients with metastatic triple negative breast cancer (mTNBC). The company will now focus on the global extensive-stage small cell lung cancer (ES-SCLC) market and is sufficiently funded to achieve anticipated profitability in the second half of 2025. Management will host a webcast and conference call today at 8:30 AM ET to discuss the results and future plans. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is August 07, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.


Disclaimer-

This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider seeking advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice. The information in this report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products.

Kalkine is not responsible for, and does not guarantee, the performance of the investments mentioned in this report This report may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services..

Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this report or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.